American EnVivo Pharmaceuticals locates European HQ in Leiden's Bio Science Park
American biotech company EnVivo Pharmaceuticals is locating its European headquarters in the Leiden Bio Science Park. This choice in favour of Leiden reinforces the international reputation of the Leiden Life Science cluster.
Deciding factors
The ageing of the population makes treatments for such illnesses as Alzheimer's even more important.
The decision to locate in Leiden was the result of an extensive analysis by EnVivo of potential locations to house the company's European activities. As well as the advantages of the Leiden Bio Science Park, the proximity of Schiphol airport was one of the deciding factors. The choice in favour of an office on the Schipholweg, close to Leiden Central Station, was prompted by assistance and advice from the Netherlands Foreign Investment Agency (NFIA), the West Holland Foreign Investment Agency (WFIA) and the Leiden Bio Science Park foundation.
EnVivo Pharmaceuticals
EnVivo Pharmaceuticals Inc. carries out research and develops treatment methods for disturbances to the central nervous system (CNS). EnVivo originates from Watertown, a suburb of Boston, Massachusetts. The company focuses on converting the available research into CNS therapies that slow down the development of diseases. EnVivo's best known product is the alpha-7 nicotinic acetylcholine receptor agonist that has successfully passed the second phase of clinical trials for treatments for schizophrenia and Alzheimer's disease.
(8 August 2012/West Holland Foreign Investment Agency)